GLB-001 / GluBio Therap - LARVOL DELTA

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: GluBio Therapeutics Inc. | Trial primary completion date: Oct 2025 ➔ Jul 2026

First-in-human • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

GLB-001-02: A Study of GLB-001 in Patients With Myeloid Malignancies (clinicaltrials.gov) - P1 | N=108 | Recruiting | Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Myelogenous Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • JAK2

A Study of GLB-001 in Patients With Myeloid Malignancies (clinicaltrials.gov) - P1 | N=108 | Not yet recruiting | Sponsor: Hangzhou GluBio Pharmaceutical Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Essential Thrombocythemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • JAK2

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: GluBio Therapeutics Inc.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology